Activin and Inhibin

EP1013 (F1013) is a broad-spectrum caspase selective inhibitor, used in the research of type 1 diabetesIn VivoEP1013 (1, 3, 10 mg/kg) significantly improves marginal islet mass function. Two animals in the 10 mg/kg EP1013 treatment group exhibit

EP1013 (F1013) is a broad-spectrum caspase selective inhibitor, used in the research of type 1 diabetesIn VivoEP1013 (1, 3, 10 mg/kg) significantly improves marginal islet mass function. Two animals in the 10 mg/kg EP1013 treatment group exhibit

EP1013 (F1013) is a broad-spectrum caspase selective inhibitor, used in the research of type 1 diabetesIn VivoEP1013 (1, 3, 10 mg/kg) significantly improves marginal islet mass function. Two animals in the 10 mg/kg EP1013 treatment group exhibit

EP2 receptor antagonist-1 (compound 1) is a potent, reversible, and agonist dependent allosteric prostaglandin EP2 receptor antagonist. EP2 receptor antagonist-1 shows anti-inflammatory effectsForm:SolidIC50&amp: Target:EP2.

EP2 receptor antagonist-1 (compound 1) is a potent, reversible, and agonist dependent allosteric prostaglandin EP2 receptor antagonist. EP2 receptor antagonist-1 shows anti-inflammatory effectsForm:SolidIC50&amp: Target:EP2.

EP2 receptor antagonist-1 (compound 1) is a potent, reversible, and agonist dependent allosteric prostaglandin EP2 receptor antagonist. EP2 receptor antagonist-1 shows anti-inflammatory effectsForm:SolidIC50&amp: Target:EP2.

EP3 antagonist 3 (compound 2) is an orally active, potent and selective EP3 antagonist, with a pK i of 8.3. EP3 antagonist 3 shows excellent pharmacokinetic properties. EP3 antagonist 3 can be used for overactive bladder (OAB)

EP3 antagonist 3 (compound 2) is an orally active, potent and selective EP3 antagonist, with a pK i of 8.3. EP3 antagonist 3 shows excellent pharmacokinetic properties. EP3 antagonist 3 can be used for overactive bladder (OAB)

EP3 antagonist 3 (compound 2) is an orally active, potent and selective EP3 antagonist, with a pK i of 8.3. EP3 antagonist 3 shows excellent pharmacokinetic properties. EP3 antagonist 3 can be used for overactive bladder (OAB)

EP3 antagonist 3 (compound 2) is an orally active, potent and selective EP3 antagonist, with a pK i of 8.3. EP3 antagonist 3 shows excellent pharmacokinetic properties. EP3 antagonist 3 can be used for overactive bladder (OAB)

EP3 antagonist 3 (compound 2) is an orally active, potent and selective EP3 antagonist, with a pK i of 8.3. EP3 antagonist 3 shows excellent pharmacokinetic properties. EP3 antagonist 3 can be used for overactive bladder (OAB) researchIC50&amp:

EP4 receptor antagonist 1 is a highly potent and selective competitive prostanoid EP4 receptor antagonist for cancer immunotherapy . EP4 receptor antagonist 1 inhibits human and mouse EP4 receptor with IC 50 s of 6.1 nM and 16.2 nM, respectively. IC